2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157578
    COX-2-IN-38 1018480-97-1 98%
    COX-2-IN-38 (compound 52*) is a potent inhibitor of COX-2, with the IC50 value of 79.4 nM.
    COX-2-IN-38
  • HY-15762R
    Valdecoxib (Standard) 181695-72-7
    Valdecoxib (Standard) is the analytical standard of Valdecoxib. This product is intended for research and analytical applications. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
    Valdecoxib (Standard)
  • HY-157725
    C18:1 LPA 799279-68-8 98%
    C18:1 LPA, a bioactive lipid derived from membrane phospholipids, plays a crucial role in various cellular processes and is found in blood plasma, where it is linked to neurological disorders, inflammation, and cancer.
    C18:1 LPA
  • HY-15790R
    Elobixibat (Standard) 439087-18-0
    Elobixibat (Standard) is the analytical standard of Elobixibat (HY-15790). This product is intended for research and analytical applications. Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
    Elobixibat (Standard)
  • HY-15790S
    Elobixibat-d5 98%
    Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
    Elobixibat-d5
  • HY-158300
    HCY/BSA 98%
    HCY/BSA is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    HCY/BSA
  • HY-15851R
    Revefenacin (Standard) 864750-70-9
    Revefenacin (Standard) is the analytical standard of Revefenacin. This product is intended for research and analytical applications. Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM.
    Revefenacin (Standard)
  • HY-15853A
    MK-7246 S enantiomer 2310135-53-4 98%
    MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.
    MK-7246 S enantiomer
  • HY-158571
    17-Phenoxy trinor prostaglandin F2α 2162157-41-5 98%
    17-Phenoxy trinor prostaglandin F2α is a PGF2α analog.
    17-Phenoxy trinor prostaglandin F2α
  • HY-158623
    (±)13(14)-DiHDPA 1345275-24-2 98%
    (±)13(14)-DiHDPA ((±)13,14-DiHDPE) a metabolite of Docosahexaenoic acid (DHA; HY-B2167) by P450 (CYP) metabolic pathways.
    (±)13(14)-DiHDPA
  • HY-159477
    SARS-CoV-2-IN-92 2123489-12-1 98%
    SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II.
    SARS-CoV-2-IN-92
  • HY-159595
    PCSK9-IN-29 1233353-86-0 99.44%
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity.
    PCSK9-IN-29
  • HY-159686
    Aclidinium 727649-81-2 98%
    Aclidinium is a long-acting muscarinic antagonist and long-acting β2-adrenoceptor (β2-AR) agonist with bronchodilator activity. Aclidinium can reduce hyperinflation of the lungs and increase lung function and exercise endurance time. Aclidinium is used in research on chronic obstructive pulmonary disease (COPD).
    Aclidinium
  • HY-159853
    C14-A1 98%
    C14-A1 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads.
    C14-A1
  • HY-159905
    HPK1-IN-54 3048537-48-7 98%
    HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC50 value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy.
    HPK1-IN-54
  • HY-159913
    AYK004-C1 3031612-92-4 98%
    AYK004-C1 is a TLR agonist. AYK004-C1 can be used to prepare immune adjuvants.
    AYK004-C1
  • HY-159914
    AYK004-B1 3031612-91-3 98%
    AYK004-B1 is a TLR7 agonist (EC50=0.2265 nM). AYK004-B1 can be used to prepare immune adjuvants.
    AYK004-B1
  • HY-159916
    AYK004 3031612-90-2 98%
    AYK004 is a TLR7/8 agonist that enhances immune responses by activating the TLR signaling pathway. AYK004 is an adenine derivative with a favorable hydrophilic-lipophilic balance, which improves the loading capacity and stability in immunoadjuvant systems such as liposomes, while reducing the side effects of the immunoadjuvant system in systemic immunity .
    AYK004
  • HY-159919
    UM-3006 1927013-87-3 98%
    UM-3006 is a highly efficient TLR7/8 agonist that enhances immune responses by activating the TLR signaling pathway. UM-3006 holds significant research and application potential in the fields of vaccine adjuvants and immune diseases.
    UM-3006
  • HY-159920
    PSB-22269 98%
    PSB-22269 is a GPR17 antagonist with a Ki value of 8.91 nM. PSB-22269 further demonstrated significant inhibitory effects in cAMP and G protein activation assays. Molecular docking studies revealed that the binding site of PSB-22269 contains positively charged arginine residues and a hydrophobic pocket. PSB-22269 provides a strategy to promote remyelination and holds promise for research in the field of multiple sclerosis.
    PSB-22269
Cat. No. Product Name / Synonyms Application Reactivity